GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » Research & Development

NRX Pharmaceuticals (STU:B1Q) Research & Development : €10.61 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. NRX Pharmaceuticals's Research & Development for the three months ended in Mar. 2024 was €1.61 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €10.61 Mil.


NRX Pharmaceuticals Research & Development Historical Data

The historical data trend for NRX Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals Research & Development Chart

NRX Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Research & Development
8.73 17.93 16.07 12.26

NRX Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.41 3.58 3.11 2.32 1.61

NRX Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €10.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NRX Pharmaceuticals  (STU:B1Q) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


NRX Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


NRX Pharmaceuticals (STU:B1Q) Business Description

Traded in Other Exchanges
Address
1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals (STU:B1Q) Headlines

No Headlines